Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06862739
PHASE4

Glycemic Control with Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Sponsor: Nabiqasim Industries (Pvt) Ltd

View on ClinicalTrials.gov

Summary

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Official title: Glycemic Control with Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

800

Start Date

2025-04

Completion Date

2026-04

Last Updated

2025-03-06

Healthy Volunteers

No

Interventions

COMBINATION_PRODUCT

Empagliflozin+Linagliptin+Metformin

Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients